Breakthrough results for Jardiance as heart failure med

6 July 2021

Adding to the wealth of support for their diabetes drug Jardiance (empagliflozin) and its already established cardiovascular benefits, German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) today released new top-line Phase III data.

The EMPEROR-Preserved Phase III trial met its primary endpoint, establishing Jardiance as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF).

For full-year 2020, worldwide Jardiance revenue was $1.154 billion, an increase of 22% year-on-year, as reported by Lilly. For Boehringer, the drug generated net sales of 2.48 billion euros ($2.94 billion), up 15.3%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK